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Acute Aortic Dissection and Intramural Hematoma
A Systematic Review
Firas F. Mussa, MD; Joshua D. Horton, MD; RameenMoridzadeh, MD; Joseph Nicholson, PhD;
Santi Trimarchi, MD, PhD; Kim A. Eagle, MD
IMPORTANCE Acute aortic syndrome (AAS), a potentially fatal pathologic process within the
aortic wall, should be suspected in patients presenting with severe thoracic pain and
hypertension. AAS, including aortic dissection (approximately 90% of cases) and intramural
hematoma, may be complicated by poor perfusion, aneurysm, or uncontrollable pain and
hypertension. AAS is uncommon (approximately 3.5-6.0 per 100000 patient-years) but
rapid diagnosis is imperative as an emergency surgical procedure is frequently necessary.
OBJECTIVE To systematically review the current evidence on diagnosis and treatment of AAS.
EVIDENCE REVIEW Searches of MEDLINE, EMBASE, and the Cochrane Register of Controlled
Trials for articles on diagnosis and treatment of AAS from June 1994 to January 29, 2016,
were performed. Only clinical trials and prospective observational studies of 10 or more
patients were included. Eighty-two studies (2 randomized clinical trials and 80 observational)
describing 57 311 patients were reviewed.
FINDINGS Chest or back pain was themost commonly reported presenting symptom of AAS
(61.6%-84.8%). Patients were typically aged 60 to 70 years, male (50%-81%), and had
hypertension (45%-100%). Sensitivities of computerized tomography andmagnetic
resonance imaging for diagnosis of AAS were 100% and 95% to 100%, respectively.
Transesophageal echocardiography was 86% to 100% sensitive, whereas D-dimer was 51.7%
to 100% sensitive and 32.8% to 89.2% specific among 6 studies (n = 876). An immediate
open surgical procedure is needed for dissection of the ascending aorta, given the high
mortality (26%-58%) and proximity to the aortic valve and great vessels (with potential for
dissection complications such as tamponade). An RCT comparing endovascular surgical
procedure to medical management for uncomplicated AAS in the descending aorta (n = 61)
revealed no dissection-related deaths in either group. Endovascular surgical procedure was
better thanmedical treatment (97% vs 43%, P < .001) for the primary end point of “favorable
aortic remodeling” (false lumen thrombosis and no aortic dilation or rupture). The remaining
evidence on therapies was observational, introducing significant selection bias.
CONCLUSIONS AND RELEVANCE Because of the highmortality rate, AAS should be considered
and diagnosed promptly in patients presenting with acute chest or back pain and high blood
pressure. Computerized tomography, magnetic resonance imaging, and transesophageal
echocardiography are reliable tools for diagnosing AAS. Available data suggest that open
surgical repair is optimal for treating type A (ascending aorta) AAS, whereas thoracic
endovascular aortic repair may be optimal for treating type B (descending aorta) AAS.
However, evidence is limited by the paucity of randomized trials.
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A cute aortic syndrome (AAS) is an acutely presenting,potentially fatalpathologywithin thewallof theaorta.1AASconsists of aortic dissection, intramural hematoma, and
penetrating atherosclerotic ulcer (eTable 1 in the Supplement). The
incidenceofAAS ranges from3.5 to6.0per 100000patient-years
in the general population, but increases in patients aged 64
to 74 years (27 per 100000patient-years) and older than 75 years
(35 per 100000 patient-years).2-4 Acute aortic dissection com-
prises 85% to 95% of all AAS.5-8
Acute aortic dissection and intramural hematoma share simi-
lar clinical features andcomplications, buthaveuniquepathophysi-
ologicmechanisms (Figure 1 and Figure 2). Rupture of the vasa va-
sorumis the incitingevent in intramuralhematoma,causingbleeding
into theaorticmedia.9 Intra-
mural hematoma can then
progress to acute aortic dis-
section if the intimal layer
ruptures, termed the entry
tear, and, therefore, intra-
muralhematomamayrepre-
sent the onset of an aortic
dissection. Presence of an
entry tear is the pathognomonic diagnostic characteristic of acute
aortic dissection,which typically occurs spontaneously rather than
in the context of intramural hematoma. Classification of AAS fol-
lows2 systems, Stanford10 andDeBakey11 (Figure3). Stanford type
A lesions involvetheascendingaorta,whereas typeB lesionsarecon-
fined to thedescendingaorta.TheDeBakeysystemaccounts forpa-
thologyaffectingboth theascendinganddescendingaorta (type I),
only the ascending segment (type II), or only the descending por-
tion (type III).
Sudden onset of severe thoracic pain with severe hyperten-
sion should raise suspicion for AAS.1,9 A characteristic examination
finding is variation inpulseorbloodpressurebetween theupperex-
tremities. Electrocardiography and chest x-ray are often equivocal,
and computed tomography (CT) or magnetic resonance imaging
(MRI) should not be delayed if AAS is suspected.1,5,9 Treatment is
either medical or surgical, depending on the location of the lesion
andthepresenceofcomplications (malperfusionsyndrome[branch-
vessel involvement resulting in end-organ ischemia], aneurysm, or
intractable symptoms or blood pressure).1,5,9-11Medical therapy in-
cludes tight control of blood pressure, long-term lipid-lowering
agents if indicated,smokingcessation,andotheratherosclerosis risk-
reduction measures. β-Blockers are the preferred antihyperten-
siveagentbecause they reducebothbloodpressureandheart rate9;
goal blood pressure in the acute setting is systolic pressure of less
than 120mmHgormean pressure of less than 80mmHg. Calcium
channel blockers are less well studied, but are acceptable second-
line blood pressure–lowering agents given the low risk for reflex
tachycardia.9 In contrast, vasodilators promote reflex tachycardia
and increaseaorticwall stressandshouldnotbeusedfor initialblood
pressuremanagement.Opioids (eg,morphine)arepreferredforpain
control.Asurgicalprocedure iseitheropenorendovascular (thoracic
endovascular aortic repair [TEVAR]).9
This review summarizes the published evidence on diagnosis
andmanagement of AAS (Table 1) with a specific focus on diagnos-
tic methods and the evolving roles of medical therapy and TEVAR
compared with a traditional open surgical procedure.
Methods
Asystematic searchwasperformed forAAS followingPreferredRe-
porting Items for a Systematic ReviewandMeta-analysis (PRISMA)
guidelines.12 The searchwasperformed inMEDLINE, EMBASE, and
the Cochrane Register of Controlled Trials from June 1994 to Janu-
ary29, 2016. Search terms includedboth subject headings andkey-
words for aortic diseases, intramural hematoma, aortic dissection,
penetrating ulcer, aortic ulcer, aortic syndrome, optimal medical
therapy, open repair, endovascular treatment, stent graft, therapy,
and diagnosis. Searches were limited to clinical trials and observa-
tional studiespublished inEnglish.Completesearchstringsare found
in eAppendix 2 in the Supplement. Only clinical trials and prospec-
tive observational studies of acute AAS (<2 weeks since symptom
onset) with 10 or more patients were included. Two independent
reviewers screened articles independently. Reviewer disagree-
mentwas resolvedbydiscussion.TheCochraneRiskofBias toolwas
used to evaluate themethodological quality of all included studies
(eTable 7 in theSupplement).13 The strengthof theevidenceaswell
as any recommendationsweregradedaccording to theOxfordCen-
tre for Evidence-Based Medicine criteria (eAppendix 1 in the
Supplement).14 Heterogeneity among the included studies pre-
cluded meta-analysis. Results were extracted into data tables and
qualitative analysiswasperformedbasedon the typeof pathology.
Results
We retrieved 2061 studies, 1905 of which were ineligible based on
titleandabstractscreening.Theremaining156studieswerescreened
in full text, 74were ineligible, leaving82 studies for inclusion in this
review (eFigure in the Supplement). From the 82 studies included,
therewere2 randomized clinical trials (RCTs) and80observational
cohortstudiesdescribing57 311patients.Studiescontributingtodata
synthesis but not explicitly discussed in the following text are sum-
marized in eTables 2 through 6 in the Supplement.
The literature on treatment options for AAS is significantly lim-
ited given the relative lack of RCTs. The clinical status andpresence
of complicationsare typically important factors indecidingwhether
AAS acute aortic syndrome
CT computerized tomography
MRI magnetic resonance imaging
TEE transesophageal
echocardiography
TEVAR thoracic endovascular
aortic repair
Key Points
Question What are optimalmethods for diagnosing andmanaging
acute aortic syndrome (AAS) basedon current evidence?
Findings Computed tomography, magnetic resonance imaging,
and transesophageal echocardiography have high sensitivity and
specificity for diagnosing AAS. Open repair of the ascending aorta
appears optimal for repairing AAS in the ascending aorta (type A),
and although endovascular repair has been used with increasing
frequency for management of AAS in the descending aorta
(type B), evidence is associated with significant selection bias
and clinical trial evidence is lacking.
Meaning Because of the highmortality rate, AAS should be
considered and diagnosed promptly in patients presenting with
acute chest or back pain and high blood pressure. For
management, optimal type of repair depends on type of AAS.
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topursuemedicalmanagementor surgical procedure.Unstablepa-
tients and those with more severe symptoms may be less likely to
be referred for a surgical procedureand therefore, observational re-
sults are likely tobeaffectedby selectionbias. For this reason,most
of the evidence is level IIB, resulting in grade B recommendations.
Only 2 RCTs15,16 evaluating acute and chronic uncomplicated de-
scending aortic dissection have been completed.
Acute Aortic Dissection
Clinical Presentation of Acute Aortic Dissection
Average ages of patients presenting with acute aortic dissection
ranged from age 48 to 67 years (median age, 61) and 50% to 81%
weremen.5,17-22Amongobservational studies,hypertensionwas the
most common comorbidity, observed in 45% to 100% of patients
with acute aortic dissection (3620 of 4674 patients), followed by
smoking history at 20% to 85% (545 of 760 patients). Other com-
mon comorbidities included chronic renal insufficiency (3%-79%;
68 of 394 patients), chronic obstructive pulmonary disease (5%-
36%; 95 of 845 patients), and stroke or transient ischemic attack
(0%-20%; 49 of 542 patients).5,17-22 A recent analysis of 30 412
middle-aged patients (mean age, 58.0 years [SD, 7.6]) with a 20-
year follow-up reported an aortic dissection incidence of 15 per
100000 patient-years.20
Inastudyof464patients fromthe InternationalRegistryofAor-
ticDissection(IRAD,amulticenter researchcoalitionfounded in1996
thatcontinuouslyevaluates themanagementandoutcomesofacute
aortic dissection), chest or back pain was the most common pre-
senting symptom (84.8%), often described as “sharp” (64.4%).22
Figure 1. Anatomy of the Aorta and Pathogenesis of Acute Aortic Syndrome
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whichmay erode through the intima creating a communication between the
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Weak carotid, brachial, or femoral pulse (pulse deficit) (30%); hy-
potension (>25%); and syncope (13%) were also reported. An aor-
tic regurgitationmurmurwas present in 31.6%,more commonly in
type A acute aortic dissection.18 Patients with type B acute dissec-
tion reportedmore abdominal pain than those with type A (42.7%
vs 21.6%, respectively; P < .001).18 In IRAD, presentation included
syncope (33.9%), congestiveheart failure (19.7%), or stroke (11.3%)
and 6.4% had painless aortic dissection.22 In a recent study, 84 of
258 patients (33%)with acute type A dissections and 19 of 140 pa-
tients (21%) with acute type B dissection had the complication of
acuteheart failureonpresentation,whichsignificantlydelayed time
to a surgical procedure (13 hours for patientswith congestive heart
failure vs 8.5 hours for patients without congestive heart failure,
P < .01).23
Among patients with aortic dissection in an IRAD study, there
were more men than women (67.9%, 732 of 1078 patients).24
Figure 2. Clinical Imaging of Aortic Dissection and Intramural Hematoma FromDifferent Patients
A
C D
B
Type A lesions
Aortic dissection, axial views
Aortic dissection, sagittal views
Intramural hematoma
Type B lesions
E F A, Type A aortic dissection, axial
contrast enhanced computed
tomography (CT) at the level of the
pulmonary artery bifurcation
(star = false lumen). B, Type B aortic
dissection, axial contrast enhanced
CT at the level of the carina
(star = false lumen). C, Type A aortic
dissection, sagittal contrast enhanced
CT (arrowhead = dissection plane).
D, Type B aortic dissection, sagittal
contrast enhanced CT. Note the
false lumen along the inner
(anterior) curve of the aorta.
(arrowhead = dissection plane).
E, Type A intramural hematoma,
coronal contrast enhanced CT
(star = hematoma). F, Type B
intramural hematoma, sagittal
contrast enhanced CT. Arrowheads
point to hematomawithin the wall
of the descending aorta. Note
heterogeneous hyperintensity
corresponding to blood.
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Compared with men, women with aortic dissection presented at
older ages (49.7% of women with aortic dissection who were older
than 70 years vs 28.6% of men with aortic dissection who were
older than 70 years) with atypical symptoms and delayed diagno-
sis, leading to highermortality (30.1% for women vs 21.0% formen,
P = .001).24 In the absence of Marfan syndrome, dissection was
pregnancy-related in 2 of 346 female IRAD patients (0.6%).24 Also
in IRAD, black patients with aortic dissection were younger with
more cocaine abuse, uncontrolled hypertension, and diabetes
compared with white patients, although in-hospital and 3-year
mortality was not different.25,26
Assessment and Diagnosis of Acute Aortic Dissection
The utility of electrocardiography and chest x-ray in AAS is limited
to rulingoutotherpathologies thatpresentwithchestpain (eg,myo-
cardial infarction). For type A lesions, chest x-ray can demonstrate
widened mediastinum, but 20% to 28% of dissections lack this
finding.17,27 X-ray should not be used exclusively to diagnose aortic
dissection. Cardiac troponin T is frequently elevated in AAS and is
associated with delayed diagnosis.28
Initial diagnostic evaluation includes CT or MRI and poten-
tially transesophageal echocardiography29 (Figure 2 and Table 2;
eTable 2 in the Supplement). For acute dissection in our review,
the sensitivities and specificities of CT (100% and 100%, respec-
tively), MRI (95%-100% and 94%-98%, respectively), and trans-
esophageal echocardiography (TEE; 86%-100% and 90%-100%,
respectively) were comparable.18,30,31,34,35,47 However, transtho-
racic echocardiography did not perform as well, with sensitivity of
73.7% to 100.0% (median, 86.9%) and specificity of 71.2% to
91.0% (median, 81.1%).48,49
Early diagnosis of acute dissection is imperative. For situations
in which imaging may not be possible (eg, no scanner available or
patient’s clinical statusdeteriorating), serologic biomarkers reflect-
ing early damage to the aortic wall are an attractive diagnostic mo-
dality (Table 2). Currently, the most studied of these biomarkers is
D-dimer,37 with a sensitivity of 51.7% to 100.0% (median, 93.5%)
and specificity of 32.8% to 89.2% (median, 54.0%) at a minimum
cutoff level of 0.5 μg/mL (to convert to nmol/L, multiply by
5.476).37-41 Elevated D-dimer is also associated with increased in-
hospital mortality.42 Soluble elastin fragments,43 smooth muscle
myosinheavychain,45matrixmetalloproteinase8,44andsoluble lec-
tin-likeoxidized low-density lipoprotein receptor 146havealsobeen
studied (Table 2); however, the lack of RCTs prevents any conclu-
sions regarding their ability to improve outcomes.
Treatment and Prognosis of Acute Aortic Dissection
TypeAAorticDissection |Reported short-termmortality (30-dayor
in-hospital mortality) for type A acute aortic dissection in the re-
viewedstudies (all level IIB)was 13%to 17%(median, 14%) foropen
surgical procedure and 0%-16% (median, 7%) for TEVAR (Table 3;
eTable 3 in the Supplement). Seventy-two percent of patientswith
typeAacuteaorticdissection in IRADweremanagedsurgically.Medi-
calmanagementwas reserved for advancedage, significant comor-
bidity, patient refusal, or death prior to planned surgical operation.
Opensurgicalprocedurewasassociatedwitha26%in-hospitalmor-
talitycomparedwith58%formedicalmanagement.18BasedonIRAD
data, 4distinct time frames fromsymptomonset toemergencyde-
partment presentation were identified: hyperacute (0-24 hours),
acute (2-7 days), subacute (8-30 days), and chronic (30 days).50
In the hyperacute and acute period, survival with surgical manage-
mentwas92%and84%,respectively, comparedwith82%and51%,
respectively, for medical management.50 However, these data are
limited by the observational study design.
In a large German registry, 20% to 30% of 2317 patients with
acute type A dissection presented with neurological dysfunction
(hemiparesis or hemiplegia, paraparesis or paraplegia, transient is-
chemic attack, delirium, or decreased level of consciousness) with
12.3%resolving followingsurgical procedure.Postoperatively,9.5%
of these patients experienced new neurological symptoms.
Malperfusion syndrome, dissection of supra-aortic vessels, and in-
creased operative timewere risk factors for new-onset postopera-
tive neurological dysfunction.51 In the only US Food and Drug Ad-
ministration–approved, physician-sponsored investigator device
exemption of endovascular management of type A aortic dissec-
tion, 9 off-label and 5 on-label procedures were performed be-
tween 2006 and 2015.52 Six patients had acute and 5 had chronic
type A aortic dissections, and all procedures were technically suc-
cessful with a 30-daymortality of 7.1%.
Type B Aortic Dissection | Reviewed studies (level IIB) reported
30-day or in-hospitalmortality for type B acute aortic dissection of
0% to 27% (median, 7%) for medical treatment, 13% to 17% (me-
dian, 16%)foropensurgicalprocedure,and0%to18%(median,6%)
for TEVAR (Table 3; eTable 4 in the Supplement). One IRAD study
found that typeBacuteaortic dissection treatedwithmedicalman-
agement was associated with a 9.5% in-hospital mortality com-
pared with 29% in the surgical cohort.7 The surgical cohort had
Figure 3. Stanford and DeBakey Classification of Acute Aortic Syndrome
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Stanford type A lesions involve the ascending aorta, whereas type B lesions are
confined to the descending aorta. The DeBakey system accounts for pathology
affecting both the ascending and descending aorta (I), only the ascending
segment (II), or only the descending portion (III).
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malperfusion syndrome or evidence of periaortic hematoma as an
indication for a surgical procedure. Thus, difference in illness sever-
ity between the 2 groups is likely to have influenced the results.
Fattori and colleagues55 compared 853 patients with medical
management for typeBdissection to 276 receivingTEVAR in apro-
pensity-matchedanalysis.AlthoughTEVARpatientspresentedwith
more complications (pulse deficit, malperfusion syndrome, shock,
stroke, spinal cord ischemia, visceral ischemia, or renal failure), in-
hospitalmortalitywasnotdifferent and5-year cumulativeprobabil-
ity ofmortalitywas lower for TEVAR than formedicalmanagement
(15.5% vs 29.0%, respectively; P = .02). An investigational device
exemption study of TEVAR for complicated (malperfusion or rup-
ture) type B dissections (n = 50) reported a 30-day mortality (pri-
mary end point) of 8% (4 of 50 patients).57
Recently, the Level IB ADSORB (Acute Dissection: Stent Graft
or Best Medical Treatment) trial15 compared medical therapy with
TEVAR inanRCTof61patientswithuncomplicatedacute typeBaor-
tic dissection. The primary end point was “favorable aortic remod-
eling” (false lumen thrombosis and no aortic dilation or rupture) at
1 year. Therewerenoaortic ruptures in either groupand thedegree
of aortic dilationwas similar. However, patientswithmedical treat-
ment had less false lumen thrombosis relative to those receiving
TEVAR(97%forTEVARvs43%formedical treatment,P < .001).Fur-
thermore, at 1-year follow-up, theTEVARgroupdemonstratedmore
favorableaortic remodelingrelativetothosetreatedmedically (mean
false lumen diameter, 18.5 mm vs 25.1 mm, respectively; P < .001;
maximumtrue lumendiameter, 32.2mmvs25.5mm, respectively;
P < .001 for TEVAR and medical management).15 Although the In-
vestigationofStentGrafts inAorticDissectionWithExtendedLength
of Follow-up (INSTEAD-XL) trial investigated chronic typeBdissec-
tions (which are excluded fromthis review), it provides someof the
best Level IB data for long-term outcomes following TEVAR in un-
complicated type B dissection.16 INSTEAD-XL randomized 140 pa-
tients with stable, chronic (>14 days from symptom onset) type B
dissection toeithermedical treatment andTEVARormedical treat-
mentalone.Althoughaorta-specificmortality forTEVARwashigher
in the first 12 months (7.5 vs 3.0 per 100 person-years, respec-
tively), TEVAR was associated with better outcomes than medical
treatment alone for this end point (6.9% vs 19.3%, respectively;
P = .04) as well as disease progression (4.1% vs 28.1%, respec-
tively; P = .004) at 5-year analysis. However, TEVAR did not re-
duce all-cause mortality (11.1% vs 19.3%, respectively; P = .13).16
Intramural Hematoma
Clinical Presentation of Intramural Hematoma
Intramural hematoma typically occurs in patients with severe ath-
erosclerotic disease.5 Fewer than 10% of cases will resolve
spontaneously,9whereas 16%to47%will progress todissection.62
Average ages of patients presenting with intramural hematoma
ranged from58 to 71 years (median age, 68 years)5,17,19,21,32,58,59,63
and 50% to 81%weremen.5,17,19,21,58,59,63 Among all AAS, 6.3% of
cases (n = 178) consisted of intramural hematoma in a study from
the IRAD.5 This rate is lower than other included studies (range,
11%-39%).19,32,33,61,64-67 In IRAD,58%of intramuralhematomaswere
typeBandabrupt chest andbackpainwere themost commonpre-
senting symptoms at 77.9% and 61.6%, respectively.5 Hyperten-
sionwaspresent in68%to96%ofpatients5,17,19,21,32,60,63 and 18%
to 67%were smokers.17,63Ta
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Assessment and Diagnosis of Intramural Hematoma
In IRADand another cohort (n = 103), the electrocardiographywas
normal in 35% to 37%.5,17 Chest x-ray showed widened mediasti-
num in 50% to 70% of patients.5,17 Pleural effusion was seen in
26%.17 Transesophageal echocardiography (TEE) had a sensitivity
of 96.5% to 99.6% and specificity of 92.3% to 98.5%.19,32,65
CTandMRI are thegold standards for thediagnosis of intramu-
ral hematoma (Figure 2 and Table 2; eTable 5 in the Supplement).
Furthermore,CT identificationof intimaldefects (erosionof theves-
selwall in discrete locations) in patientswith intramural hematoma
is associated with progression to dissection.63 Forty-four patients
with medically treated, uncomplicated type B intramural hema-
tomawere followed over amean of 450 days; 87%with initial inti-
mal abnormality experienced progressive disease compared with
only9%in thosewithout (P < .001). Intramural hematomaswith fo-
cal areas of dissection demonstrated 80% and 40% 5- and 8-year
freedom from dissection-relatedmortality, respectively.67
Treatment and Prognosis of Intramural Hematoma
In-hospital and 30-daymortality of patientswith intramural hema-
toma (Table 3; eTable 6 in the Supplement) was reported by 6 evi-
dence level IIB studies including 309 patients formedical manage-
ment (4%-19%; median, 8%),7,17,27,58-60 3 level IIB studies with 75
patients for open surgical repair (11%-24%;median, 17%),5,17,21 and
by 4 level IIB studies with 61 patients for TEVAR (0%-6%;median,
2%).5,58,59,61 However, these rates and the following data are lim-
ited by the observational study design.
In a study of 86 cases of AAS, patients with “moderate” intra-
muralhematoma(withouthemodynamic instability,persistentpain,
impending rupture, or ruptured aneurysm) were deemed suitable
formedicalmanagement.Definitive surgical therapywas indicated
in “severe” intramural hematomapatientswhodemonstrated these
complications.Of 26patientsmanagedmedically, 6patients (23%)
had spontaneous regression and 7 patients (27%) required a surgi-
cal procedure.21
Table 3. Reported Outcomes for Treatment of Acute Aortic Syndromea
Pathology
Medical Open Surgical Procedure TEVAR
Studies, No.
Patients,
No.
Mortality
Range, %b Studies, No.
Patients,
No.
Mortality
Range, %b
Studies,
No.
Patients,
No.
Mortality Range,
%b
All AASsc 14 1512 0-29 13 2653 0-50 25 1460 0-21
All AAD 6 1413 0-27 7 2530 13-17 20 1134 0-18
Type A AAD 118 17 7.6 318,50,51 2275 13-17 352-54 38 0-16
Type B AADd 67,15,55 1126 0-27 57,15,55,56 255 13-17 207,15,55,57 1128 0-18
IMH
(type A and B)
67,17,27,58-60 309 4-19 35,17,21 75 11-24 45,58,59,61 61 0-6
Abbreviations: AAD, acute aortic dissection; AAS, acute aortic syndrome;
IMH, intramural hematoma; TEVAR, thoracic endovascular aortic repair.
a Majority of data from observational studies, rates subject to bias.
b 30-day or in-hospital mortality.
c Includes penetrating atherosclerotic ulcer.
d Studies mentioned in the Results section cited (eTable 4 in the Supplement).
Table 2. Reported Sensitivity and Specificity of Diagnostic Tools for Acute Aortic Syndromea
Diagnostic Toolb
Studies,
No.c
Patients,
No. Threshold
All AASsd,e Acute Aortic Dissectione Intramural Hematomae
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
CT27 1 49 100
(86.3-100)
100 100
(86.3-100)
100
(85.6-100)
MRI29-31 3 116 95.0-100 94.0-98.0 95.0-100 94.0-98.0
TEE17,27,29,30,32,33 6 520 86.0-100 90.0-100 86.0-100 90.0-100 96.5-99.6 92.3-98.5
TTE34,35 2 228 73.7-100 71.2-91.0 73.7-100 71.2-91.0 100 91.0
Intravascular
ultrasound36
1 28 100 100
D-dimer37-42 6 876 >0.5-0.7 μg/mL 51.7-100 32.8-89.2 51.7-100 32.8-89.2
Elastin degradation
products43
1 609 >3 SD above mean
of healthy patients
99.8
(99.1-100)
99.8
(99.1-100)
MMP 8/944 1 126 >3.6 ng/mL 100
(93.2-100)
9.5
(3.9-18.5)
Smooth muscle
myosin heavy chain45
1 27 >10 ng/mL 90.0
(78.7-100)
97.0 90.0
(78.7-100)
97.0
Soluble lectin-like
oxidized LDLR 146
1 19 >150 pg/mL 89.5 94.3
Abbreviations: AAS, acute aortic syndrome; CT, computed tomography;
LDLR 1, low-density lipoprotein receptor 1; MMP 8/9, Matrix metalloproteinase
8/9; MRI, magnetic resonance imaging; TEE, transesophageal
echocardiography; TTE, transthoracic echocardiogram.
SI conversion factor: To convert D-dimer to nmol/L, multiply by 5.476.
a Empty cells indicate data that was not reported in included studies.
b The reference standard for diagnostic tools was confirmation at operation or
autopsy or, in some cases, CT or MRI confirmation.
c All included studies were cross-sectional.
d Including acute aortic dissection, intramural hematoma, and penetrating
atherosclerotic ulcer.
e Range of values reported if more than 1 study reviewed for a given outcome. If
a single study, 95% confidence interval reported by that study is listed in
parentheses when available.
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In 27patientswith typeB intramural hematomamanaged con-
servatively and followed for amean of 33months, 47%underwent
regression, 14%remained stable, and39%progressed toaortic dis-
section or enlargement.17 Another study compared early medical
therapy (n = 11) withmedical therapy plus TEVAR in intramural he-
matomacomplicatedby intimalerosion (n = 8).Atamean follow-up
of 17.6months, 10of 11medically treatedpatientsdemonstrated re-
gression and 5 of these patients (45%) had complete resolution of
their intramural hematoma. All those treated with TEVAR had
resolution.59
Song and colleagues60 compared type A intramural hema-
tomato typeB in 127patients. Pericardial andpleural effusionswere
morecommonandmortality rateswerehigher inpatientswith type
A (7%forpatientswith typeAvs 1% forpatientswith typeB).How-
ever, rates of regression or progression to dissection were similar.
In IRAD, in-hospital mortality for type A intramural hematomawas
40% for medical therapy and 24% for surgical therapy. For type B
hematoma, in-hospitalmortalitywas4%formedical treatment and
20% for surgical therapy.5
Medical therapywas comparedwithTEVAR in56patientswith
type B intramural hematoma. TEVAR was reserved for those with
maximumaortic diametermore than 45mm, hematoma thickness
more than 10mm, or sustained chest or back pain despitemaximal
medical therapy. Technical success was 100%with no progression
or mortality in the TEVAR group (n = 33). In the medically treated
group (n = 23), 6patients (26%)progressed todissectionand2pa-
tients (9%)died.58Becausethesestudiesareobservational, thequal-
ity of evidence is limited (Table 4).
Discussion
Presentation, diagnosis, and treatment of AAS subtypes are sum-
marized in Table 1. Rapid diagnosis is important given the morbid-
ity and mortality associated with delayed treatment. AAS has var-
ied clinical presentations, many of which may overlap with other
acute cardiovascular events such asmyocardial ischemia or stroke.
CT and MRI remain the gold standard for diagnosis of AAS,
but TEE canbe a reliable alternative. The 2014European Society of
Cardiology (ESC) supported use of TEE with level IIA (grade C)
recommendation,69 which is in agreement with the evidence pre-
sented in this review (level IIB).More evidence is needed regarding
the use of serologic biomarkers to diagnose AAS. Current evidence
does not support their use as a diagnostic tool for AAS.
Table 4 presents treatment recommendations from this re-
view aswell as from current societal guidelines. All patients should
receive initialmedical therapy(Table1) tocontrolpainandbloodpres-
sure (level I, grade C).69 Type A AAS necessitates immediate open
surgical repair (level I, grade B), though endovascular approaches
to type A lesions are under investigation.52
For all AAS in the descending aorta, the available (observa-
tional) data reveals that both medical and endovascular manage-
ment are correlated with lower early mortality than an open surgi-
cal procedure. For uncomplicated type B acute aortic dissection,
significant selection bias exists inwhich typically sicker, higher-risk
patients are chosen for TEVAR and are still associated with out-
comes not different than those treated medically. Therefore, con-
troversy remains regarding whether medical management (level I,
gradeBorC) or TEVAR (level IIA, gradeBorC) is thebest treatment
choice foruncomplicated typeBdissections.Clinical guidelinespro-
posed by a multisociety task force in 2010 and by the ESC in 2014
includeda class I (gradeBandC, respectively) recommendation for
medical management of type B aortic dissection in the absence of
life-threatening complications.68,69 Less controversyexists regard-
ing the treatment of type B dissection complicated by malperfu-
sion syndrome, progression of dissection, enlarging aneurysm, or
inability to control blood pressure or symptoms. For these pa-
tients, TEVAR is the first-line therapy (level I, gradeBor C) anddata
Table 4. Treatment Recommendations for Acute Aortic Syndrome
Stanford Type
ACCF/AHA/AATS/ACR/
ASA/SCA/SCAI/SIR/
STS/SVM 201068a Level (Grade)b ESC 201469c Level (Grade)b This Review Level (Grade)b
Aortic Dissection
A Open surgical procedure I (B) Open surgical procedure I (B) Open surgical procedure I (B)
B
Complicatedd Surgical proceduree I (B) TEVAR I (C) TEVAR I (C)
Uncomplicatedd Medical therapy I (B) Medical therapy or TEVAR I (C) or IIA (B) Medical therapy or TEVAR I (C) or IIA (C)
Intramural Hematoma
A
Complicatedd Open surgical procedure IIA (C) Open surgical procedure I (C) Open surgical procedure IIA (C)
Uncomplicatedd Not mentioned Not mentioned Medical therapy IIA (C)
B
Complicatedd Surgical proceduree IIA (C) TEVAR IIA (C) TEVAR IIA (C)
Uncomplicatedd Medical therapy I (B) Medical therapy I (C) Medical therapy IIA (C)
Abbreviations: ESC, European Society of Cardiology; TEVAR, thoracic
endovascular aortic repair.
a American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines, American Association for Thoracic Surgery,
American College of Radiology, American Stroke Association, Society of
Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and
Interventions, Society of Interventional Radiology, Society of Thoracic
Surgeons, and Society for Vascular Medicine.
bOxford Centre for Evidence-BasedMedicine—Levels of Evidence (eAppendix 1
in the Supplement).14
c European Society of Cardiology.
dMalperfusion syndrome, progression of dissection, enlarging aneurysm,
inability to control blood pressure or symptoms.
e No specification of open vs TEVAR.
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fromthis reviewsupports this recommendation.However,with ret-
rograde arch involvement, open surgical procedure or hybrid
(open + endovascular) approaches are appropriate.57
Complicated intramural hematoma is associatedwith progres-
sion to dissection; therefore, in accordance with societal guide-
lines and the results of this review, surgical procedure shouldbe the
intervention of choice: open surgical procedure for type A (level I
or IIA, gradeC)andTEVARfor typeB(level IIA, gradeC).21,58,59Sixty-
one percent to 91% of uncomplicated type B intramural hemato-
mas are stable or regress with medical therapy. Medical treatment
should be the initial approach to this pathologywith a surgical pro-
cedure reserved for complications (pericardial effusion, shock,peri-
aortic hematoma, large aneurysm).69
Much of the evidence in this review consists of observational
data with significant risk of selection bias. For example, in 1 IRAD
study,18medicalmanagementof typeAdissectionwas reserved for
advancedage, comorbidity,patient refusal,ordeathprior toplanned
surgicalprocedure.Therefore, thehighermortality inpatientstreated
medicallymaybeduetoselectionbias.Alternatively, inanother IRAD
cohortexamining typeBdissections, an indication for a surgical pro-
cedure included the presence of complications. Thus, a benefit of
this therapy overmedical managementmay have been blunted by
selection bias. Randomized data on treatment options for this pa-
thology are needed, but ethical concerns of withholding poten-
tially life-saving surgical procedure for the sake of randomization
make implementationof these studiesdifficult. Perhaps the2avail-
ableRCTs for typeBdissection15,16 can serve as examples for future
study design and implementation.
Forascendingandcomplicateddescendingaorticdissection, fu-
ture research should identify patientswhomaybenefit from stent-
graft placementduring theacutephase toprevent long-termaneu-
rysmal degeneration or aorta-related mortality. In addition, AAS
involving solely the aortic arch or those originating elsewhere and
progressing into this region are not fully understood, both in terms
of natural history and best treatment options. In these situations,
further study isneeded todeterminewhetherhybrid therapy (com-
bined endovascular and open surgical approach) is efficacious.
Conclusions
Because of the high mortality rate, AAS should be considered and
diagnosedpromptly inpatientspresentingwith acute chestorback
pain and high blood pressure. Computerized tomography, mag-
netic resonance imaging,andtransesophagealechocardiographyare
reliable tools for diagnosing AAS. Available data suggest that open
surgical repair is optimal for treating type A (ascending aorta) AAS,
whereas thoracicendovascularaortic repairmaybeoptimal for treat-
ing typeB (descending aorta) AAS.However, evidence is limitedby
the paucity of randomized trials.
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